EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Salvage Proton Therapy Re-Irradiation in Recurrent Head and Neck Cancer: Outcomes and Adverse Events by Re-Irradiated Target Site

Enrique Amaya iD, Jacobo Palma iD, Roser Fayós-Solà iD, Rosa Meiriño iD, Mauricio Cambeiro iD, Ana Navarrete iD, Pablo Cabello-García iD, Alberto Viñals iD, Diego Pedrero iD, Felipe A Calvo iD, Javier Aristu iD, Javier Serrano iD

Cancers · 09.07.2026 · 18 (14) · 2207

DOI: 10.3390/cancers18142207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 09.07.2026. Verfasst von Enrique Amaya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Clinica Universidad de Navarra, 28027 Madrid, Spain. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Navarra University Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Photon re-irradiation in previously treated head and neck cancer (HNC) is constrained by cumulative normal-tissue toxicity. Pencil-beam scanning intensity-modulated proton therapy (PBS-IMPT) allows for a sharper dose conformation than conventional photon techniques, which may widen the therapeutic window in previously irradiated tissue.

Methods

Sixty-five patients with recurrent or second primary HNC were enrolled in a prospective single-institution registry and re-irradiated with PBS-IMPT between January 2020 and December 2025. Forty-five were treated with radical intent (69.2%), and 20 were treated postoperatively (30.8%), with a median prescribed dose of 66 Gy (RBE) in 30 fractions. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Locoregional control (LRC), adverse events and the prognostic impact of anatomical extent were secondary endpoints.

Results

The median follow-up was 9.3 months. The median OS was 17.2 months (95% CI 13.9–NR), with a 12-month rate of 67.1%. The median PFS was 10.1 months and the median LRC was 28.1 months. Central/skull-base involvement was associated with a non-significant trend toward worse OS (14.3 vs. 35.2 months; p = 0.062) and with significantly worse PFS (9.1 vs. 14.7 months; p = 0.037) than peripheral disease, but LRC did not differ between the groups (p = 0.240). Grade ≥ 3 oral mucositis occurred in 7.7%, with no grade 4–5 acute events. Within a median follow-up of 9.3 months, late osteoradionecrosis affected 6.2%, but late toxicity data remain preliminary given the short follow-up. Ninety-two percent of patients completed treatment.

Conclusions

PBS-IMPT re-irradiation provided adequate survival with low acute toxicity. T3–T4 stage at re-irradiation was the only variable retaining significance for PFS on multivariable analysis (HR 4.32, 95% CI 1.24–15.13; p = 0.022). The poor survival observed for central/skull-base disease on Kaplan–Meier curves disappeared after T-stage adjustment, indicating the higher concentration of advanced disease in that compartment. Multicentre prospective data and longer follow-up are needed.

Schlagwörter

Stichwörter der Autor:innen

IMPTadverse eventhead and neck cancerlocoregional controloverall survivalproton therapyre-irradiationrecurrent

Autor:innen und Institutionen

  • Department of Radiation Oncology, Clinica Universidad de Navarra, 28027 Madrid, Spain.
  • Department of Medical Physics, Clinica Universidad de Navarra, 28027 Madrid, Spain.

ORCID-Profile: Enrique Amaya, Jacobo Palma, Roser Fayós-Solà, Rosa Meiriño, Mauricio Cambeiro, Ana Navarrete, Pablo Cabello-García, Alberto Viñals, Diego Pedrero, Felipe A Calvo, Javier Aristu, Javier Serrano

Förderung

  • Navarra University Clinic

Zitieren

APA

Amaya, E., Palma, J., Fayós-Solà, R., Meiriño, R., Cambeiro, M., Navarrete, A., Cabello-García, P., Viñals, A., Pedrero, D., Calvo, F. A., Aristu, J., & Serrano, J. (2026). Salvage Proton Therapy Re-Irradiation in Recurrent Head and Neck Cancer: Outcomes and Adverse Events by Re-Irradiated Target Site. Cancers, 18(14), 2207. https://doi.org/10.3390/cancers18142207

Vancouver

Amaya E, Palma J, Fayós-Solà R, Meiriño R, Cambeiro M, Navarrete A, et al. Salvage Proton Therapy Re-Irradiation in Recurrent Head and Neck Cancer: Outcomes and Adverse Events by Re-Irradiated Target Site. Cancers. 2026;18(14):2207. doi:10.3390/cancers18142207

BibTeX
@article{Amaya2026,
  author = {Amaya, Enrique and Palma, Jacobo and Fayós-Solà, Roser and Meiriño, Rosa and Cambeiro, Mauricio and Navarrete, Ana and Cabello-García, Pablo and Viñals, Alberto and Pedrero, Diego and Calvo, Felipe A and Aristu, Javier and Serrano, Javier},
  title = {Salvage Proton Therapy Re-Irradiation in Recurrent Head and Neck Cancer: Outcomes and Adverse Events by Re-Irradiated Target Site},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2207},
  doi = {10.3390/cancers18142207}
}
Kostenlos starten →